Seattle Genetics Profile

62.37
USD 1.49  2.33%
57.51Last Month High 64.08 
62.27Trading Day  High 64.08 

Exercise or conversion by Clay Siegall of 1797 shares of Seattle Genetics subject to Rule 16b-3

Seattle Genetics Inc insider trading alert for exercise of non-qualified stock option (right to buy) by Clay Siegall, President and CEO, on October 13, 2017. This event was filed by Seattle Genetics Inc with SEC on 2017-10-13. Statement of changes in beneficial ownership - SEC Form 4. Clay Siegall is currently serves as co-founder, chairman, ceo and pres of Seattle Genetics Inc [view details]   

Seattle Genetics Summary

Seattle Genetics Inc (SGEN) is traded on NASDAQ in USA. It is located in WASHINGTON, U.S.A and employs 759 people. Seattle Genetics is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Mid-Cap' category with current market capitalization of 9.13 B. Seattle Genetics Inc conducts business under Healthcare sector and is part of Biotechnology industry. This company has 143.03 M outstanding shares of which 10.98 M shares are at this time shorted by private and institutional investors with about 9.81 trading days to cover. SEATTLE GENETICS currently holds about 452.41 M in cash with (154.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.16.
Check Seattle Genetics Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Selected Seattle Genetics Inc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Seattle Genetics Against Markets

Current Ratings  

Seattle Genetics 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
21 
Chance of
< 28% 
Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies for the treatment of cancer worldwide. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameSeattle Genetics Inc
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Specialization
Healthcare, Pharmaceuticals And Biosciences
InstrumentUSA Stock Stocks Directory
RegionNorth America
LocationWASHINGTON, U.S.A
Business Address21823 30th Drive S.E., Bothell, WA 98021, United States
ExchangeNASDAQ
CIK Number01060736.0
ISINUS8125781026
CUSIP812578102
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.seattlegenetics.com
Contact Number425 527 4000
CurrencyUSD - US Dollar

Current Sentiment - SGEN

Seattle Genetics Inc Investor Sentiment
Most of Macroaxis users are at this time bullish on Seattle Genetics Inc. What is your outlook on investing in Seattle Genetics Inc? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
SeattleSkip  Hide

Recommendations

Seattle Genetics Analyst Recommendations
Target PriceAdvice# of Analysts
57.73Hold11Odds
Seattle Genetics Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Seattle Genetics Analyst Advice  

Opportunities

Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  

Earnings

Seattle Genetics Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.42April 27, 2017
Seattle Genetics Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate